The clinical outcomes of rituximab biosimilar CT-P10 (Truxima®) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience.
Leuk Lymphoma
; 61(7): 1575-1583, 2020 07.
Article
in En
| MEDLINE
| ID: mdl-32290739
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Large B-Cell, Diffuse
/
Biosimilar Pharmaceuticals
Limits:
Humans
Language:
En
Journal:
Leuk Lymphoma
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2020
Document type:
Article
Country of publication: